Bukwang Pharm. announced that it hosted the second TVM Capital Asia Conference at Bukwang R&DCenter on October 29th, with the theme “Business Opportunities through Bridging East and West.” This invitation-only event was attended by decision makers in business development and research in pharmaceutical companies in Korea and abroad as well as investors in the biopharmaceutical field.
Dr. Myung Kee Kim of InterVest, Dr. Mirko Scherer of TVM China and Mr. Thomas Mathers of Colucid Pharmaceuticals were invited as speakers to the conference, which was co-hosted with TVM Capital Life Science. The speakers each talked about Korean pharmaceutical market’s future trend and growth strategies, China pharmaceutical market trend and investment strategies, and development and artnering of Lasmiditan, Colucid’s migraine candidate.
“It was a great event for Korean pharma companies to establish appropriate business strategies and gain collaboration opportunities with investment companies,” one of the attendees from pharmaceutical companies said. An investor who participated to the event stated that “I learned about investment strategies of global investment firms and felt it would be valuable to consider potential of biopharmaceutical companies and possibilities of collaboration with them.”
“For this year, the conference was attended by pharmaceutical and investment companies who were invited before the event. This allowed more intimate networking between the attendees,” Bukwang personnel said. “In the future, we will keep providing networking events between pharmaceutical and investment companies in order to generate new business opportunities,” the personnel added.
TVM Capital Conference series provides a hub for information exchange for biopharmaceutical and investment industry for pharmaceutical companies, bioventures and investment firms. The Conferences have been regularly held in Canada and Austria. The first of its kind in Asia was hosted by Bukwang at Bukwang’s facilities last October, with the theme “Global Cooperation in New Drug Development.”
TVM Capital Life Science, based in North America and Europe, has more than 30 years of experience in investment and R&D of more than 130 biopharmaceutical companies and products. TVM Capital Life Science is a global venture capital firm which also introduces new pipelines and bioventures to the investors of its funds. Bukwang Pharm. has been investing in TVM Capital Life Science Series VII Fund as a Limited Partner and Strategic Partner, along with Eli Lilly.